Results of Annual General Meeting
Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, April 28, 2021: Hutchison China MediTech Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 28, 2021 were duly passed. The poll results of the resolutions were as follows:
|
|
Number of Votes (%)* |
|||||
|
Resolutions |
For
|
Against
|
Withheld# |
|||
|
1 |
To consider and adopt the audited financial statements and the reports of the directors and independent auditor for the year ended December 31, 2020. |
630,497,481 (91.5978%) |
57,834,970 (8.4022%) |
1,916,690 |
||
|
|
||||||
|
2(A) |
To re-elect Mr Simon To as a director. |
582,822,673 (88.1122%) |
78,632,253 (11.8878%) |
28,794,215 |
||
|
|
||||||
|
2(B) |
To re-elect Mr Christian Hogg as a director. |
687,962,021 (99.6700%) |
2,278,095 (0.3300%) |
9,025 |
||
|
|
||||||
|
2(C) |
To re-elect Mr Johnny Cheng as a director. |
686,432,366 (99.4486%) |
3,805,770 (0.5514%) |
11,005
|
||
|
|
||||||
|
2(D) |
To re-elect Dr Weiguo Su as a director. |
687,380,226 (99.5857%) |
2,859,890 (0.4143%) |
9,025 |
||
|
|
|
|
|
|
||
|
2(E) |
To re-elect Dr Dan Eldar as a director. |
650,371,921 (94.2242%) |
39,867,120 (5.7758%) |
10,100 |
||
|
|
|
|
|
|
||
|
2(F) |
To re-elect Ms Edith Shih as a director. |
650,086,941 (94.2126%) |
39,934,200 (5.7874%) |
228,000 |
||
|
|
|
|
|
|
||
|
2(G) |
To re-elect Mr Paul Carter as a director. |
605,583,736 (87.7354%) |
84,654,830 (12.2646%) |
10,575 |
||
|
|
|
|
|
|
||
|
2(H) |
To re-elect Dr Karen Ferrante as a director. |
621,140,866 (89.9895%) |
69,096,195 (10.0105%) |
12,080 |
||
|
|
|
|
|
|
||
|
2(I) |
To re-elect Mr Graeme Jack as a director. |
605,033,971 (87.6565%) |
85,199,140 (12.3435%) |
16,030 |
||
|
|
|
|
|
|
||
|
2(J) |
To re-elect Professor Tony Mok as a director. |
649,699,566 (94.1266%) |
40,540,520 (5.8734%) |
9,055 |
||
|
|
|
|
|
|
||
|
3 |
To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorize the board of directors to fix the auditor's remuneration. |
689,797,116 (99.9367%) |
436,820 (0.0633%) |
15,205 |
||
|
|
|
|
|
|
||
|
4 |
Ordinary Resolution No. 4(A) |
: |
To grant a general mandate to the directors of the Company to issue additional shares. |
687,700,756 (99.6324%) |
2,537,355 (0.3676%) |
11,030 |
|
|
|
|
|
|
||
|
|
Special Resolution No. 4(B) |
: |
To disapply pre-emption rights (general power). |
685,992,219 (99.3861%) |
4,237,012 (0.6139%) |
19,910 |
|
|
|
|
|
|
||
|
|
Special Resolution No. 4(C) |
: |
To disapply pre-emption rights (in connection with an equity raise). |
574,881,172 (83.2890%) |
115,343,064 (16.7110%) |
24,905 |
|
|
|
|
|
|
||
|
|
Ordinary Resolution No. 4(D) |
: |
To grant a general mandate to the directors of the Company to repurchase shares of the Company. |
689,852,331 (99.9464%) |
370,175 (0.0536%) |
26,635 |
|
|
|
|
|
|
|
|
|
5 |
Special Resolution |
: |
To change the English name of the Company to "HUTCHMED (China) Limited" and the Chinese name of the Company to "和黃醫藥（中國）有限公司". |
690,238,916 (99.9997%) |
2,195 (0.0003%) |
8,030 |
* Percentages rounded to 4 decimal places
# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.
The change of name will be effective once the Register of Companies has issued a certificate of incorporation on change of name.
As at the date of the AGM, the number of issued shares of HUTCHMED was 744,515,660, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
|
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
|
Annie Cheng, Vice President |
+1 (973) 567 3786 |
|
|
|
Media Enquiries |
|
|
Americas - Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
|
Europe - Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) HUTCHMED@fticonsulting.com |
|
Asia - Joseph Chi Lo / Zhou Yi, Brunswick |
+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) |
|
|
|
Nominated Advisor |
|
|
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited |
+44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
